Interferon-γ therapy reduces blood leukocyte levels in patients with atopic dermatitis:: Correlation with clinical improvement
Interferon-γ therapy reduces blood leukocyte levels in patients with atopic dermatitis:: Correlation with clinical improvement
复制标题
DOI：
10.1006/clim.1999.4731
复制
发表时间：
1999-07-01
影响因子：
8.6
通讯作者：
Cooper, KD
中科院分区：
文献类型：
--
作者：
Ellis, CN;Stevens, SR;Cooper, KD
特应性皮炎（AD）是一种细胞免疫和体液免疫异常的慢性炎症性皮肤病。皮下注射重组人干扰素-γ (IFN-γ) 为 AD 患者提供治疗益处。与预期相反，IFN-γ 不会导致 AD 患者循环 IgE 水平升高的降低。我们试图确定 IFN-γ 治疗的细胞靶点，以解释其临床益处。因此，我们通过多参数流式细胞术评估了接受 IFN-γ (n = 10) 或安慰剂 (n = 11) 治疗的 AD 患者与未经治疗的正常志愿者 (n = 14) 的血液白细胞亚群。接受治疗的患者白细胞、嗜酸性粒细胞和淋巴细胞计数减少。与正常人相比，AD 患者活化的大单核细胞中 CD4/CD8 比率降低，这一现象可通过 IFN-γ 治疗部分纠正。临床改善与白细胞（r = 0.9，P = 0.0003）、嗜酸性粒细胞（r = 0.7，P = 0.035）和淋巴细胞（r = 0.8，P = 0.013）计数的减少以及大淋巴细胞中 CD4/CD8 比率的正常化（r = 0.9，P = 0.04）相关。数据表明 INF-gamma 在 AD 中的两种潜在作用模式。一种机制代表 AD 中选定的免疫异常的正常化；第二种机制可能是循环炎症细胞的适度减少。 AD 的 IFN-γ 治疗是否充分可能取决于这些变化的带来。 (C) 1999 年学术出版社。
Atopic dermatitis (AD) is a chronic inflammatory skin disease with abnonmalities of both cellular and humoral immunity. Subcutaneous recombinant human interferon-gamma (IFN-gamma) provides therapeutic benefit to AD patients. In contrast to expectations, IFN-gamma does not cause a decrease in the elevated levels of circulating IgE levels in AD patients, We sought to determine cellular targets of IFN-gamma treatment that might explain its clinical benefit. Therefore, we evaluated blood leukocyte subsets by multiparameter flow cytometry in AD patients receiving IFN-gamma (n = 10) or placebo (n = 11) therapy compared to untreated normal volunteers (n = 14). Treated patients demonstrated reductions in WBC, eosinophil, and lymphocyte counts. Compared to normals, there was a reduced CD4/CD8 ratio in AD patients among activated, large mononuclear cells that was partially corrected with IFN-gamma treatment. Clinical improvement correlated with reductions in WBC (r = 0.9, P = 0.0003), eosinophil (r = 0.7, P = 0.035) and lymphocyte (r = 0.8, P = 0.013) counts, and with normalization of the CD4/CD8 ratio among large lymphocytes (r = 0.9, P = 0.04). The data indicate two potential modes of actio:n for INF-gamma in AD. One mechanism represents normalization of selected immunologic abnormalities in AD; a second mechanism may be the modest reduction of circulating inflammatory cells. Adequacy of IFN-gamma therapy of AD may depend on bringing about these changes. (C) 1999 Academic Press.